Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas
- 1 July 1990
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-hodgkin's lymphomasCancer, 2006
- Randomized Trial of Chemotherapy Versus Chemotherapy Plus Radiotherapy for Stage I-II Hodgkin's DiseaseJNCI Journal of the National Cancer Institute, 1988
- Combined modality treatment for stage I–II non-hodgkin's lymphomas: CVP versus BACOP chemotherapyInternational Journal of Radiation Oncology*Biology*Physics, 1988
- Chemotherapy followed by consolidation radiation therapy for the treatment of clinical stage ii aggressive histologic type non-hodgkin's lymphomaCancer, 1988
- Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data.Journal of Clinical Oncology, 1988
- Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy.Journal of Clinical Oncology, 1987
- Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin's lymphomas.Journal of Clinical Oncology, 1985
- The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962–1984International Journal of Radiation Oncology*Biology*Physics, 1985
- Combined modality therapy in stage III and stage IIIE diffuse large cell lymphomasCancer, 1984
- Sequential non-cross-resistant chemotherapy regimens (MOPP and CAVmP) in Hodgkin's disease stage IIIB and IVCancer, 1983